Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $-87.58M.
ENTERPRISE VALUE (EV)
$-87.58M
BridgeBio Oncology Therapeutics Inc.
Market Cap
$283.87M
Enterprise Value (EV)
$-87.58M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $283.87M | $-87.58M |
| Indaptus Therapeutics, Inc. (INDP)vs › | $285.37M | $277.82M |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | $238.73M |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.83M | $249.47M |
| Sagimet Biosciences Inc. (SGMT)vs › | $287.29M | $123.34M |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | $212.88M |
| Standard BioTools Inc. (LAB)vs › | $288.35M | $46.41M |
| SAB Biotherapeutics, Inc. (SABS)vs › | $276.14M | $273.01M |
| Fate Therapeutics, Inc. (FATE)vs › | $274.50M | $317.74M |
| Larimar Therapeutics, Inc. (LRMR)vs › | $293.47M | $205.74M |
Market Cap
$283.87M
Total Debt
$2.24M
Cash
$373.69M
Enterprise Value
$-87.58M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
